{'fraction_non_alphanumeric': 0.021346469622331693, 'fraction_numerical': 0.009852216748768473, 'mean_word_length': 5.48936170212766, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prenatal Genetic Diagnostic Testing in the Era of Cell Free Fetal DNA For Aneuploidy Screening [10D]

INTRODUCTION: Prenatal screening for fetal aneuploidy has improved tremendously since the incorporation of cell-free DNA (cfDNA) in to the genetic screening armamentarium. Despite its improved detection rate of aneuploidy, this remains a screening tool and not designed to provide diagnostic information. This study aimed to assess whether initiation of cfDNA screening at the University of Illinois at Chicago (UIC) in January 2012 influenced the acceptance of prenatal diagnostic testing in at-risk women.